Kewaunee Scientific price to free cash flow KEQU

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: 8.7×
10-year median: 13.2×
Against its 10-year history: 29th; percentile: 0 is its lowest day, 100 its highest
10-year range: 5.1× to 387×
Peer median: 12.1×

Kewaunee Scientific's price to free cash flow is 8.7× as of Oct 23, 2026.

That is below its ten-year median of 13.2×, lower than on 71% of days in the last ten years.

Over that time it ranged from 5.1× in Apr 2026 to 387× in Dec 2019.

The median for 9 medical instruments and supplies stocks of a similar size is 12.1×.

Price to free cash flow over time

median 13.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.7×	5.1×	23.8×
2025	21.3×	5.7×	41.6×
2024	11.5×	6.8×	16.5×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	81.2×	79.7×	83.1×
2020	15.6×	15.2×	33.5×
2019	33.8×	10.8×	387×
2018	18.6×	14.1×	34.5×
2017	15.6×	6.8×	15.6×
2016	13.5×	10.3×	24.0×
2015	31.5×	7.2×	31.5×
2014	7.5×	7.4×	14.2×
2013	8.3×	5.2×	115×
2012	5.4×	3.2×	6.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest Kewaunee Scientific's size, closest first, today.

Company	Price to free cash flow
KEQUKewaunee Scientific	8.7×
APTAlpha Pro Tech	9.7×
PDEXPro DEX	29.5×
NEPHNephros	n/m
UTMDUtah Medical Products	20.6×
INFUInfuSystem	12.1×
EMBCEmbecta	2.3×
TCMDTactile Systems Technology	20.0×
MDXGMimedx	n/m
MOVMovado	9.8×
Peer median	12.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Kewaunee Scientific

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.